" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "
NCT ID: NCT05585944
Last Updated: 2022-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2022-11-01
2023-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Expression of Immune Checkpoint CD28 rs1980422-related Single-nucleotide Polymorphisms in the Primary Immune Thrombocytopenia
NCT05468866
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
NCT05093257
Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment
NCT07059910
The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids
NCT06568913
Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP)
NCT05371743
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control
healthy participants
Genotyping of rs1883832C/T related single-nucleotide polymorphism
Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
cases
cases of immune thrombocytopenic purpura
Genotyping of rs1883832C/T related single-nucleotide polymorphism
Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Genotyping of rs1883832C/T related single-nucleotide polymorphism
Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient with newly diagnosed ITP
* patient age \> 1 year and \< 65 years and both sexes are included.
Exclusion Criteria
* patient with persistent ITP, patient with secondary immune thrombocytopenia
* patient age \< 1 year or \> 65 years.
1 Year
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nagwa Mohamed Aboelmahasen
assisstant lecturer of clinical and chemical pathology department, Sohag university hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University hospitals
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Elham O Hamed, Professor
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Magdy M Amin, Professor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Behzad MM, Asnafi AA, Jalalifar MA, Moghtadaei M, Jaseb K, Saki N. Cellular expression of CD markers in immune thrombocytopenic purpura: implications for prognosis. APMIS. 2018 Jun;126(6):523-532. doi: 10.1111/apm.12853.
Chen JM, Guo J, Wei CD, Wang CF, Luo HC, Wei YS, Lan Y. The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus. BMC Genet. 2015 Oct 16;16:121. doi: 10.1186/s12863-015-0279-8.
Favaloro EJ. How to Generate a More Accurate Laboratory-Based International Normalized Ratio: Solutions to Obtaining or Verifying the Mean Normal Prothrombin Time and International Sensitivity Index. Semin Thromb Hemost. 2019 Feb;45(1):10-21. doi: 10.1055/s-0038-1667342. Epub 2018 Aug 22.
Morodomi Y, Kanaji S, Won E, Ruggeri ZM, Kanaji T. Mechanisms of anti-GPIbalpha antibody-induced thrombocytopenia in mice. Blood. 2020 Jun 18;135(25):2292-2301. doi: 10.1182/blood.2019003770.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-22-10-21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.